• André Y Denault, Ronald G Pearl, Robert E Michler, Vivek Rao, Steven S L Tsui, Rainald Seitelberger, Matt Cromie, Elisabet Lindberg, and Andrea M D'Armini.
• Department of Anesthesiology, Montreal Heart Institute and Université de Montréal, Montreal, Canada. Electronic address: andre.denault@umontreal.ca.
• J. Cardiothorac. Vasc. Anesth.. 2013 Dec 1;27(6):1212-7.

ObjectiveTo evaluate the efficacy of tezosentan in reducing the incidence of right ventricular (RV) failure and associated mortality in patients with pre-existing pulmonary hypertension. The primary endpoint was the proportion of patients with RV failure during weaning from cardiopulmonary bypass (CPB), assessed 30 minutes after the end of CPB.DesignMulticenter, double-blind, randomized, placebo-controlled trial.SettingThirty-one cardiac surgical centers in 14 countries.ParticipantsTwo hundred seventy-four patients with pulmonary hypertension aged ≥ 18 years scheduled to undergo cardiac surgery.InterventionIntravenous tezosentan (5 mg/h) during surgery and up to 24 hours afterwards (1 mg/h), or matched placebo.Measurements And Main ResultsOne-hundred thirty-three patients received tezosentan and 141 placebo. RV failure occurred in 30 patients (10.9%), 37% of whom died. There was no difference in the incidence of RV failure between the two treatment groups (relative risk reduction: 0.07 [95% CI-0.83, 0.53; P = 0.8278]).ConclusionA reduction in RV failure with tezosentan was not observed in this study.(Current Controlled Trials, identifier NCT00458276).Copyright © 2013 Elsevier Inc. All rights reserved.

39 keywords...

hide…